2310079N02Rik Inhibitors
Chemical inhibitors of 2310079N02Rik can modulate the protein's activity through various molecular pathways. Staurosporine, a well-known protein kinase inhibitor, exerts its effects by inhibiting protein kinase C, among other kinases. This broad-spectrum inhibition can prevent phosphorylation events necessary for the activation of 2310079N02Rik, leading to reduced activity of the protein. Similarly, Rapamycin acts by specifically inhibiting the mTOR pathway, a central regulator of cell growth and proliferation. The inhibition of mTOR can lead to a decrease in 2310079N02Rik activity, as this protein may be downstream of mTOR signaling. LY294002 targets the PI3K/Akt pathway, blocking the actions of phosphoinositide 3-kinases and consequently inhibiting the Akt signaling pathway. Given that 2310079N02Rik may rely on Akt signaling for its activity, the action of LY294002 can suppress its functional role within the cell.
Further, both PD98059 and U0126 are inhibitors of MEK, which acts upstream of ERK in the MAP kinase pathway. Inhibition of MEK by these chemicals can prevent the activation of ERK and subsequently reduce the functional activity of 2310079N02Rik if it is regulated by this pathway. SB203580 and SP600125 target other MAP kinases, with SB203580 selectively inhibiting p38 MAP kinase, and SP600125 inhibiting JNK. The inhibition of these kinases can impede the functional activity of 2310079N02Rik if it is involved in pathways regulated by p38 or JNK. Inhibition of tyrosine kinases by Dasatinib, which targets BCR-ABL and Src family kinases, can also lead to the reduced activity of 2310079N02Rik if it is associated with these signaling routes. Sorafenib and Sunitinib inhibit multiple kinases, including RAF, VEGFR, and PDGFR. By blocking these kinases, they can alter the signaling pathways that control the activity of 2310079N02Rik. Lastly, Erlotinib and Gefitinib inhibit the EGFR tyrosine kinase, which can lead to the downregulation of 2310079N02Rik activity if it is a part of the EGFR signaling pathway. Through these diverse mechanisms, chemical inhibitors can modulate the functional activity of 2310079N02Rik within cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting protein kinase C (PKC), which is directly involved in the regulation of many proteins, it can inhibit the phosphorylation and subsequent activation of 2310079N02Rik, leading to a decrease in its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is part of the mTOR signaling pathway that regulates cell growth and proliferation. Since 2310079N02Rik is involved in these cellular processes, its functional activity is inhibited when mTOR is blocked, due to the dependency on mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinases (PI3K). By blocking PI3K, it inhibits the Akt signaling pathway, which is involved in cell survival and proliferation. Inhibition of this pathway can lead to a functional inhibition of 2310079N02Rik, which may rely on Akt signaling for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of the ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, which may be necessary for the functional activity of 2310079N02Rik, thus leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another inhibitor of MEK, preventing the activation of the ERK pathway. As with PD98059, by blocking MEK, U0126 can inhibit the downstream effects on proteins regulated by ERK, including 2310079N02Rik, thereby inhibiting its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in the regulation of protein translation and cellular stress responses. By inhibiting p38, SB203580 can suppress the activity of proteins regulated by this kinase, including 2310079N02Rik, resulting in functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the control of cell proliferation and apoptosis. Inhibition of JNK can lead to the functional inhibition of 2310079N02Rik if it is regulated by the JNK signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. Tyrosine kinases are involved in activating signaling pathways that regulate various cellular processes. By inhibiting these kinases, Dasatinib can inhibit the functional activity of 2310079N02Rik if it is downstream of these pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR. These kinases are part of signaling pathways that regulate cell proliferation and survival. By inhibiting these kinases, Sorafenib can functionally inhibit 2310079N02Rik if it relies on these pathways for its activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, including PDGF and VEGF receptors. By inhibiting these receptors, Sunitinib can disrupt the signaling cascades they regulate, potentially leading to functional inhibition of 2310079N02Rik if it is part of these pathways. | ||||||